High-dose bolus exposure of rats to ethylene glycol (EG) causes developmental toxicity mediated by a metabolite, glycolic acid (GA), whose levels increase disproportionately when its metabolism is saturated. However, low-level exposures that do not saturate GA metabolism have a low potential for developmental effects. Toward the goal of developing EG risk assessments based on internal dose metrics, this study examined the differences between fast (bolus) and slow (continuous infusion) dose-rate exposures to EG on developmental outcome and pharmacokinetics. Time-mated female CD rats received sc bolus injections of 0, 1000, or 2000 mg/kg/day of EG on gestation day (GD) 6-15 once daily, whereas three corresponding groups were given the same daily doses as an infusion administered continuously from GD 6-15 via an sc implantable pump. In the sc bolus groups, increases in 11 fetal malformations (major defects) and 12 variations (minor alterations) were seen at the 2000 mg/kg/day dose level, whereas increases in 2 malformations and 2 variations occurred at 1000 mg/kg/day. In contrast, equivalent daily doses of EG given slowly via infusion did not cause any developmental effects. A pharmacokinetics time course was then conducted to compare GD 11-12 kinetics from oral bolus (gavage) exposure versus sc infusion of EG. Although dose rate had a modest impact (8-to 11-fold difference) on peak EG levels, peak levels of GA in maternal blood, kidney, embryo, and exocoelomic fluid were 59, 100, 49, and 56 times higher, respectively, following gavage versus the same dose given by infusion. These data illustrate how high-dose bolus exposure to EG causes a dramatic shift to nonlinear GA kinetics, an event which is highly unlikely to occur following exposures to humans associated with consumer and worker uses.
Studies in rats and mice have shown that large bolus doses of ethylene glycol (EG) can cause developmental toxicity (Carney, 1994) . In rats, a lowest-observable-effect level (LOEL) dose of 1000 mg/kg/day given by gavage on gestation days (GD) 6-15 reduced fetal body weights and caused axial skeleton malformations, whereas higher doses resulted in fetal deaths and a greater incidence and severity of axial skeletal and other morphological alterations (Neeper-Bradley et al., 1995) . Similar effects were seen after a single sc bolus injection (! 2800 mg/kg) of EG on GD 10 (Khera, 1991) . In contrast, EG was not developmentally toxic following dietary exposures as high as 1000 mg/kg/day or dermal exposures up to 3549 mg/ kg/day (Maronpot et al., 1983; Tyl et al., 1995c) . Rodent inhalation studies on EG have identified developmental effects only at very high aerosol concentrations, which were well above expected and measured workplace or ambient exposure levels (Tyl et al., 1995a,b) .
Based on a substantial body of in vitro and in vivo evidence (Carney et al., 1996 (Carney et al., , 1999 Klug et al., 2001; Munley et al., 1999) , it is now well accepted that the teratogenic and embryotoxic effects of EG in rodents are caused by an intermediary metabolite, glycolic acid (GA; Fig. 1 ). The doseand route-dependent profile for EG's developmental toxicity correlates with pharmacokinetic (PK) data showing a dosedependent saturation of GA metabolism, leading to a disproportionately large increase in GA levels at high doses. For example, GA accounted for only 1-2% of the EG dose eliminated in the urine of rats and mice given iv bolus doses up to 200 mg/kg but constituted greater than 20% of the dose eliminated in urine following EG doses ! 1000 mg/kg (Marshall, 1982) . In both nonpregnant and pregnant rats (GD 10) given EG via gavage, the dose-dependent shift to nonlinear GA kinetics was evident at dose levels ! 500 mg/kg (Pottenger et al., 2001) . The point at which GA kinetics become nonlinear just slightly precedes the apparent threshold for developmental toxicity in rats based on a no-observed effect level (NOEL) of 500 mg/kg/day and a lowest-observed effect level (LOEL) of 1000 mg/kg/day, suggesting that this dose-dependent transition is required for developmental toxicity. In contrast to bolus exposures, there was no evidence of a shift to nonlinear kinetics following dermal exposure, even at doses up to 1000 mg/kg (Frantz et al., 1996a) , consistent with the lack of developmental toxicity via this route.
The correlation between GA kinetics and developmental toxicity has led to further efforts to define safe levels of exposure based on internal dosimetry of GA, rather than applied dose of EG, and to develop physiologically based pharmacokinetic models for use in risk assessment (Corley et al., 2005a) . A toxicokinetic study in pregnant rats revealed peak maternal blood GA values at the NOEL (500 mg/kg/day) and LOEL (1000 mg/kg/day) for developmental toxicity of 1.7 and 4.8mM, respectively (Pottenger et al., 2001) . These in vivo data correspond closely with in vitro rat whole-embryo culture data, which indicate a no-effect concentration of 3mM (Klug et al., 2001) . Collectively, the available data led to the hypothesis that developmental toxicity in rats requires peak GA levels > 2mM in maternal blood and > 3mM in embryo (Corley et al., 2005b) . Such high levels of GA are plausible only after high-dose bolus exposure and, conversely, would seem unlikely to occur for low dose rate and/or low-dose exposures to EG. Understanding the effect of dose rate is important to human risk assessment because human exposures to EG typically occur via the dermal or inhalation routes where the slow rate of exposure and/or absorption make saturation of GA kinetics highly unlikely (Frantz et al., 1996b; Sun et al., 1995) . Understanding the impact of dose rate can also improve the basis for interspecies extrapolations, as species differences in the rate or extent of formation of GA relative to its further metabolism affect peak GA concentrations (Booth et al., 2004) .
This study tested the hypothesis that dose rate is a critical determinant of developmental toxicity in rats following EG exposure by comparing equivalent doses of EG given at a fast dose rate (gavage or sc bolus) versus a slow dose rate (continuous infusion via implantable pump). The impact of dose rate on the kinetics of EG, the proximate toxicant GA, and the terminal metabolite oxalic acid was quantified in maternal blood and kidney and in the embryo and exocoelomic fluid of the conceptus. The study also served to verify the validity of the proposed value of > 3mM peak GA in embryo as the critical internal dose metric for developmental toxicity in the rat.
MATERIALS AND METHODS

Test Material and Chemicals
EG and GA were purchased from the Aldrich Chemical Company (Milwaukee, WI). Oxalic acid was obtained from Sigma (St Louis, MO). Deuterated internal standards D 2 -glycolic acid and D 4 -ethylene glycol were obtained from Cambridge Isotope Laboratories, Inc. (Andover, MA), whereas the internal standard 2-butoxyethanol was obtained from the Aldrich Chemical Company. Derivatizing reagents, pentafluorobenzoyl chloride and N-(tertbutyldimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA), were also obtained from Aldrich. All other compounds and solvents were reagent grade or better. Purity of the EG test material was > 99%.
Test Animals
Time-mated female CD (CRL: CD (SD) IGS BR) rats were purchased from Charles River Laboratories (Portage, MI and Raleigh, NC), evaluated by a laboratory veterinarian, and cleared for study use. The day on which a vaginal plug was detected was considered GD 0. The rats were housed singly in rooms that maintained adequate temperature (19°C-25°C), humidity (40-70%), photocycle (12-h L:12-h D), and air-flow (12-15 changes per h) for rats and were acclimated to the laboratory for at least 4 days prior to the start of dosing. Animals were fed Purina 5002 (PMI; Nutrition International, St Louis, MO) in meal form. Feed and water were provided ad libitum. The only exception was in the gavage developmental pharmacokinetics study in which all rats were given 15 g of feed per rat (mild feed restriction based on historical feed consumption data) on the day prior to dosing to control for any effects of the feed on oral absorption. The studies were approved by the respective Institutional Animal Care and Use Committees.
Good Laboratory Practice
The developmental toxicity study and all infusions were conducted at The Dow Chemical Company and were done in compliance with Good Laboratory Practice (GLP) standards. The gavage pharmacokinetics study was conducted at Pacific Northwest National Laboratory using similar methodology and quality assurance practices but was not audited for GLP compliance.
Developmental Toxicity Study
Study design. Time-mated rats were stratified based upon GD 0 body weights and then randomly assigned to one of six groups (n ¼ 16-20 per group). Animals placed on study were uniquely identified via sc implanted transponders (BioMedic Data Systems, Seaford, DE) . Three of the groups were surgically implanted with sc infusion pumps in order to deliver targeted doses of 0, 1000, or 2000 mg/kg/day starting on GD 6 through GD 15 inclusive. Three other groups received equivalent doses of EG or vehicle control, given as sc bolus injections once each day on GD 6-15. The sc route was chosen to allow for infusion and because bolus sc injection of EG has been shown to induce axial skeleton malformations and decreased fetal body weights (Khera, 1991) . The 1000 mg/kg/day dose level was chosen because it is the LOEL from a previous oral gavage study (Neeper-Bradley et al., 1995) , whereas the 2000 mg/kg/day dose level was the highest dose of EG achievable via the sc infusion pump.
Maternal parameters included daily clinical observations, body weights, body weight gains, feed consumption, and urinalysis. On GD 21, all surviving rats were euthanized via carbon dioxide inhalation and then necropsied. Maternal liver, kidney, and gravid uterine weights were recorded, along with the number of corpora lutea, implantation sites, resorptions, and viable fetuses. All fetuses were weighed, sexed, and examined for external morphological alterations. Approximately one half of the fetuses from each litter was then stained with Alizarin Red and evaluated for skeletal alterations, whereas the remaining half was evaluated for craniofacial alterations via serial sectioning. External and skeletal alterations were classified as malformations, defined as major defects and/or deviations from the normal program of development, or as variations, which are minor alterations and/or delays in development which are not uncommon in the strain of rat used in this study. Maternal gross pathologic examinations and fetal examinations were conducted such that investigators were blind to treatment group assignment. Visceral examinations were not conducted, as visceral structures are not a major target for EG developmental toxicity (Carney, 1994) .
Tail vein blood was collected from three dams per group on the morning of GD 7, 9, 12, and 15,~3 h after dosing of the sc bolus injection groups, for analysis of EG and GA levels. Several prior studies had determined 3 h to be the time of peak blood GA levels following gavage administration of EG (Carney et al., 1999; Frantz et al., 1996a) , and similar kinetics were expected for the sc injection route based on prior data (Carney et al., 1999) . Dosing methods. Aqueous solutions for sc injection were prepared at concentrations of 300 and 600 mg/ml for the 1000 and 2000 mg/kg/day groups, respectively, and the dose volume was 0.9 ml/rat/day. The estimated doses delivered were 0, 867-1070, or 1794-2121 mg/kg/day, respectively.
The infusions were accomplished through the use of a novel 2.5-cm diameter, spring-loaded fully implantable pump (ESOX, Model V01; Access Technologies, Skokie, IL), which was custom calibrated by the supplier to deliver test material solutions at a constant rate of~0.9 ml/day. The infusion rate of each infusion pump was also confirmed in our laboratory prior to use on the study. The infusion pump included a reservoir (1.0-1.1 ml) and septum that allowed for percutaneous refilling, thus enabling delivery of relatively high doses of EG into the sc space at a constant rate over the entire GD 6-15 exposure period. There were no externalized components, thus allowing unrestricted movement by the animals.
Implantation of the infusion pumps was done on the morning of GD 6. Under isoflurane anesthesia, a transverse incision of 4-5 cm was made just caudal to the scapulae. Next, an sc pocket was created anterior to the incision via blunt dissection. The infusion pumps were then filled with either distilled water or EG solutions (300 or 600 mg/ml), inserted into the pocket, and anchored in place with surgical adhesive (Vetbond, St Paul, MN). The incision was closed with metal clips, which were removed approximately 6-8 days after surgery. The pump reservoirs were refilled each day using a 26-ga hypodermic needle inserted into the reservoir. Refill volumes were recorded each day. Any pumps that could not be refilled with at least 0.9 ml were considered to have malfunctioned, and the affected animals were removed from the study. On the morning of GD 16, any remaining contents of the pump reservoir were aspirated to terminate the exposures. The pumps remained in place (empty) for the remainder of the study. Actual doses delivered were 0, 872-1076, or 1691-2105 mg/kg/day for the 0, 1000, or 2000 mg/kg/day groups, respectively.
Analysis of the dosing solutions indicated that actual test material concentrations were 100-102% of targeted concentrations. All dosing solutions were used within previously established stability limits.
Analytical methods. Samples of maternal blood were analyzed for 12 C-EG and 12 C-GA via chemical derivatization with gas chromatography-negative ion chemical ionization-mass spectrometry (GC-NCI-MS) detection. The method is a modification of a method described previously (Carney et al., 2008) . In summary, a 100-ll aliquot of whole blood was diluted with an equal volume of 5N NaOH in a glass vial and then fortified with known amounts of D 4 -EG and 13 C 2 -GA internal standards. A 1-ml aliquot of acetone and 50-ll aliquots of pentafluorobenzoyl chloride (PFBCl) and pentafluorobenzyl bromide (PFBBr) derivatization reagents were added. The sealed vial was vortex mixed at 50°C for 30 min. A 1.5-ml aliquot of water and 1-ml aliquot of toluene were added and the sealed vial vortex mixed at room temperature for~15 s. The vial was centrifuged at 1942 3 g for 10 min and the organic layer transferred to a glass autosampler vial for GC-NCI-MS analysis. The EG and GA derivatives were analyzed using Hewlett Packard (HP) 5989X MS equipped with a HP 6890 GC and a HP 7683 autosampler (Hewlett Packard, Avondale, PA). Chromatographic separation was achieved using a J&W DB-5MS fused silica capillary column (30 m 3 0.25 mm i.d., 0.50-lm film thickness; J&W Scientific, Folsom, CA). A 1-ll aliquot was injected into an SGE Focusliner in the splitless mode for 6 s at 280°C. The GC oven was held at an initial temperature of 80°C or 0.5 min and then ramped at 12°C/min to a final temperature of 290°C. The helium carrier gas was held at a constant head pressure of 25 psi. Negative chemical ionization (NCI) was achieved using methane at 1.8 torr and a 250°C source temperature. The mass analyzer was held at 120°C, and the ions were detected with the high-energy diode held at 10 kV and the electron multiplier held at 2400 V. The MS was operated in the single-ion monitoring mode. The ions used for quantitation of the EG derivatives were 450 for the 12 C-EG analyte and 454 for the D 4 -EG internal standard. The ions used for quantitation of the GA derivatives were 269 for the 12 C-GA analyte and 271 for the 13 C 2 -GA internal standard. The analyte and internal standard ions were monitored with 150 and 100 ms dwell times, respectively. The limit of detection was 6 lg/g Statistics. Maternal body weights, body weight gains, organ weights (absolute and relative), fetal body weights, and feed consumption were evaluated by Bartlett's test for equality of variances. Based on the outcome of Bartlett's test, a parametric or nonparametric ANOVA was performed. If the ANOVA was significant, analysis by Dunnett's test or the Wilcoxon rank-sum test with Bonferroni's correction was performed. Frequency of preimplantation loss, resorptions per litter, and resorptions per fetal population and fetal alterations were analyzed using a censored Wilcoxon test with Bonferroni's correction (Haseman and Hoel, 1974) . The number of corpora lutea, implantation sites, nonviable fetuses, and viable fetuses were evaluated using a nonparametric ANOVA followed by the Wilcoxon rank-sum test with Bonferroni's correction. Pregnancy rates were analyzed using the Fisher's exact probability test with Bonferroni's correction, whereas fetal sex ratios were analyzed using a binomial distribution test. Females lacking viable fetuses were excluded from the appropriate analyses. Statistical outliers were identified using a sequential method (Grubbs, 1969 ) (a ¼ 0.02) and excluded only if justified by sound scientific reasons.
Pharmacokinetics Time-Course Study
A pharmacokinetics time course was conducted to compare slow dose rate (infusion pump) exposure with oral bolus (gavage) dosing and included multiple time points and analysis of EG, GA, and oxalic acid in various maternal and conceptus tissues/fluids. Infusion pump dosing was carried out as described previously, except that the animals were terminated on GD 11 or 12 followed by collection of maternal blood, kidneys, exocoelomic fluid, and embryos. Urine was also collected from the animals terminated on GD 12. Two additional groups (n ¼ 18 per group) of rats were administered EG by oral gavage on GD 11 at dose levels of 100 or 1000 mg/kg. These doses were chosen to be below and above the transition point to nonlinear kinetics for the GA metabolite. Subgroups of three gavage-dosed animals/time period were sacrificed at 1, 3, 6, 9, 12, and 24 h after dosing. Animals from the 24-h sacrifice were housed in metabolism cages for the collection of urine (0-12 and 12-24 h). Tissues and fluids were collected and analyzed as described for the infusion pump groups.
Specimen collection. At each scheduled sacrifice time, animals were anesthetized in an 80% CO 2 atmosphere and exsanguinated via cardiac puncture. Blood samples were collected in heparinized Vacutainers and immediately frozen on dry ice. The kidneys were immediately trimmed, weighed, and flash frozen. Each uterus was dissected to remove the decidual swellings containing the conceptuses (Cockroft, 1990) . Each conceptus was then carefully blotted and then held over an Eppendorf tube, followed by gently tearing the visceral yolk sac to release the exocoelomic fluid into the tube. Exocoelomic fluid and embryos (each pooled by litter) were weighed and flash frozen. On the morning of GD 11, all rats scheduled for termination 24 h later (GD 12) were placed in metabolism cages and urine samples from each animal were collected from 0-12 h and from 12-24 h into dry ice-cooled traps.
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To ensure completion collection of voided urine, each cage was rinsed with a minimal volume of deionized water (~10 ml), which was combined with each urine sample for analysis. All samples were stored at À80°C until analyzed.
Quality control samples. Quality control (QC) storage spikes of control blood, urine, kidneys, and exocoelomic fluid containing 36-69 lg/g (low-level) or 475-600 lg/g (high-level) EG, GA, or oxalic acid were prepared and stored at À80°C along with the study samples. Due to a small amount of control embryos available, QC samples were only prepared at a single mid-level (183-218 lg/g) of EG, GA, and oxalic acid. Aliquots of these QC controls were analyzed along with each preparation of samples from both studies to demonstrate stability or determine the potential losses of analytes over the period of time it took to complete all analyses.
Analytical methods. Samples of heparinized whole blood, urine, exocoelomic fluid, and embryos were analyzed for EG, GA, and oxalic acid by gas chromatography/mass spectrometry (GC/MS) following the general extraction and derivatization methods described in Pottenger et al. (2001) . 2-Butoxyethanol and deuterated EG and GA were utilized as internal standards. Kidneys were first homogenized in deionized water then analyzed by similar methods. At the highest dose levels, blood and kidneys were analyzed for EG using gas chromatography/flame ionization detection (GC/FID) and 2-butoxyethanol as an internal standard (GA and oxalic acid were analyzed by GC/MS). For urine samples containing very high concentrations of EG, a direct analysis of urine by GC/FID was also conducted using 2-butoxyethanol as an internal standard. Each of these methods is described briefly below.
GC/MS analyses of EG, GA, and oxalic acid were performed on a Hewlett Packard 7683 Mass Selective Detector equipped with a Hewlett Packard 6890 Plus gas chromatograph and 7683 autosampler (Hewlett Packard). Separations were achieved with a Restec RTX-5MS fused silica capillary column (30 m 3 0.25 mm i.d., 0.25-lm film thickness; Restec, Bellefonte, PA). Injections were either splitless (GA, oxalic acid) or pulsed splitless (EG) using an unpacked Restec 4 mm i.d. cyclo-double gooseneck liner. Representative chromatography conditions for GA and oxalic acid were as follows: injector temperature was 210°C and the initial oven temperature was 110°C, which was increased at 15°C/min to 200°C, with a final ramp of 25°C/min to 300°C; initial head pressure was a constant 25 psi with helium as the carrier gas. For EG, the injection temperature was 190°C and the initial oven temperature was 130°C, which was increased at 20°C/min to 200°C, with a final ramp of 50°C/min to 300°C. The initial head pressure was pulsed at 35 psi for 0.5 min followed by a constant head pressure of 25 psi with helium as a carrier gas. The masses used for quantitation of EG were 238 or 450 (depending upon column conditions), 241 or 454 for D 4 -EG, 247 for GA, 249 for D 2 -GA, and 261 for oxalic acid.
GC/FID analyses of EG were performed on a Hewlett Packard 6890 gas chromatograph equipped with an FID detector and autosampler. Separations were achieved with a J&W DB-Wax fused silica column (15 m 3 0.53 mm i.d. 3 1.0 df; J&W Scientific). For direct injection of urine, aliquots of 1.0 ll (splitless) of urine spiked with 2-butoxyethanol internal standard (250 lg/g) were injected at 220°C with an initial head pressure of 5 psi (helium) for 2 min, increasing to 10 psi at 20 psi/min. The initial oven temperature was 80°C, increasing to 125°C at 20°C/min with a final ramp of 30°C/min to 230°C. A Restek 4 mm i.d. cyclodouble gooseneck injection liner was also used. For analysis of high-dose blood and kidney extracts, the same column and injection liner were used with a constant head pressure of 7 psi (helium), injection temperature of 225°C, and initial oven temperature of 70°C for 2 min, increasing at 20°C/min to 130°C with a final ramp to 230°C at 50°C/min.
Statistics and PK calculations. Descriptive statistics (i.e., mean ± SD) were used where applicable to present the data. In some instances, only one or two samples within a group had levels of analytes above the limits of reliable quantitation (although not necessarily below the limits of detection). Rather than excluding these values, which would artifactually raise mean values, in these cases, the limit of quantitation/2 was arbitrarily used as a surrogate to calculate what is likely to be a more realistic mean ± SD for plotting and pharmacokinetic parameter estimations. Areas under the concentration (AUC) versus time curves were calculated for each analyte based on means from each group and time point in the oral gavage pharmacokinetics study according to the trapezoidal rule (Gibaldi and Perrier, 1982) . Half-lives (b-elimination phase) were determined by:
where Ke is determined from the slope of the line in the b-elimination phase.
AUCs from the infusion pump groups were calculated based on sample collection on the morning of GD 11 and 24 h later. Data from the first phase of this study (GD 6-15 infusions), as well in vitro calibrations, supported the assumption that the infusion pumps delivered at a constant rate across this period.
RESULTS
Developmental Toxicity Study
Rats in the EG bolus groups exhibited maternal toxicity consistent with that observed in many previous EG studies (reviewed in Carney, 1994) . These maternal effects (data not shown) included incoordinated gait, decreased activity (2000 mg/ kg/day only), and reddish urine (the majority of rats in both dose levels). The 2000 mg/kg/day bolus group rats exhibited statistically significant decreases in body weight gains for the GD 6-9 and 6-21 intervals as well as decreased feed consumption on GD 6-9. Body weights, body weight gains, and feed consumption were unaffected in the 1000 mg/kg/day bolus group. Urinalysis revealed increases in protein and bilirubin at both dose levels but no clear treatment-related changes were evident upon microscopic examination of the urine. At necropsy, there was a statistically identified increase in relative kidney weights at the high dose and increases in relative and absolute liver weights in the 1000 and 2000 mg/kg/day bolus groups. In contrast, no treatment-related signs of maternal toxicity were evident in rats receiving 1000 or 2000 mg/kg/day of EG via infusion pump (data not shown).
There were no significant treatment-related effects on pregnancy rates, numbers of corpora lutea, implantations, resorptions, or viable fetuses from dams given EG via sc bolus injections (Table 1) . However, fetal body weights and gravid uterine weights were decreased in the 2000 mg/kg/day bolus group, relative to the bolus control group. There were no effects on these parameters in the 1000 mg/kg/day bolus group or in either of the EG infusion groups.
The sc bolus injections of EG increased the incidence of numerous fetal malformations and variations, consistent with previous data (Neeper-Bradley et al., 1995) . Among the 2000 mg/kg/day sc bolus group fetuses, axial skeleton malformations such as thoracic hemivertebrae, extra lumbar vertebrae, missing thoracic centra, and extra, floating, fused, and missing ribs were all observed at significantly elevated incidences (Table 2) . Increased incidences of several other malformations, although not statistically identified, were considered to be treatment-related based on their consistency with prior data. These malformations ETHYLENE GLYCOL DOSE RATE 181 included dilated cerebral ventricles, fused thoracic vertebrae, fused lumbar vertebrae, and missing thoracic vertebrae. In addition, increased incidences of the following skeletal variations were noted and considered treatment related: delayed ossification of the interparietals, zygomatic, cervical, thoracic and lumbar centra, ribs and sternebrae, irregular pattern of thoracic centra, rib and sternebrae ossification, fused sternebrae, and extra site of sternebrae ossification. In the 1000 mg/kg/day sc bolus group, fetal malformations considered to be treatment related were limited to increases in extra lumbar vertebrae and extra ribs, whereas treatment-related increases in two skeletal variations (delayed ossification of cervical and thoracic centra) also were observed.
In contrast, there were no increases in any fetal malformation or variation in the EG infusion pump groups relative to controls. The malformations that did occur in the sc infusion groups were relatively few in number and affected only one fetus each and, thus, were not considered to be treatment related.
The sc bolus injections of EG resulted in maternal blood EG levels at 3 h after dosing ranging from 7.3 to 12.3-mM and from 18.6 to 24.5mM for the 1000 and 2000 mg/kg/day dose levels, respectively ( Fig. 2A) . Rats given 1000 or 2000 mg/kg/ day via infusion were sampled at approximately the same time as the bolus groups and had EG blood levels of 1.9-2.9mM and 3.7-4.5mM, respectively. As demonstrated in pilot studies (data not shown) and corroborated in Figure 2A , the sc infusion pumps maintained relatively constant blood EG levels throughout the entire period of infusion.
Levels of GA in maternal blood 3 h after sc bolus dosing ranged from 2.8 to 4.0mM (average 3.3mM) and from 5.7 to 7.5mM (average 6.3mM) for the 1000 and 2000 mg/kg/day dose levels, respectively (Fig. 2B) . In contrast, rats given 1000 or 2000 mg/kg/day of EG via sc infusion had much lower blood GA levels, ranging from 0.1 to 0.2mM (average 0.1mM) and from 0.7 to 1.1mM (average 1.0mM), respectively.
Pharmacokinetics Time-Course Study Gavage (fast dose rate). Consistent with previous data (Pottenger et al., 2001) , EG administered by gavage was rapidly absorbed, with maximal maternal blood concentrations detected at the first observed or sampled time point of 1 h (Fig. 3A) . EG showed dose-proportional kinetics between 100 and 1000 mg/kg, and clearance of EG from blood was first order (log-linear) with an elimination half-life of 1.6-1.8 h. EG levels in maternal kidney followed a similar kinetic profile to those of maternal blood, although slightly lower than blood at 1000 mg/kg. Unchanged EG was the major component found in urine at both dose levels, exhibiting dose proportionality in terms of the amount excreted over a 24-h period (Fig. 4) , and accounted for 21 or 26% of the total dose administered for the low-and high-dose level, respectively. EG levels in exocoelomic fluid and embryos were nearly identical to maternal blood, with the exception that the half-life for elimination was slightly longer than blood (2.5 h).
There was a pronounced shift from linear to nonlinear GA kinetics as the EG dose level was increased 10-fold from 100 to 1000 mg/kg (Fig. 3C) . The AUC for GA in maternal blood was 76-fold higher after dosing at 1000 mg/kg than at 100 mg/kg (Table 3 ). This observation was even more dramatic in the kidney where the AUC increased 190-fold for a corresponding 10-fold increase in administered dose. The amount of GA excreted in the urine over 24 h was 131-fold greater at the high 12.9 ± 1.8 12.9 ± 2.0 13.1 ± 2.1 14.2 ± 1.6 13.4 ± 2.9 13.9 ± 2.0 Mean no. of implantations/dam (± SD) 12.4 ± 2.8 12.3 ± 2.7 12.8 ± 2.1 13.6 ± 1.4 12.8 ± 2.6 13.6 ± 1.6 % Preimplantation loss a 5.3 ± 15.0 5.3 ± 11.6 2.9 ± 4.2 4.4 ± 4.2 4.6 ± 6.2 2.6 ± 4.5 % Implantations resorbed 3.8 5.6 5.5 3.7 8.7 6.9 % Litters with resorptions 47.1 31.3 41.2 42.9 50.0 52.9 Mean no. of viable fetuses/litter (± SD) 11.9 ± 2.9 11.6 ± 3.3 12.1 ± 2.4 13.1 ± 1.6 11.7 ± 3.1 12.7 ± 1.7 Fetal weight-sexes combined (g) (± SD) 5. (17) 186 (16) 206 (17) 183 (14) 209 (18) 216 (17) Skeletal 106 (17) 98 (16) 107 (17) 94 (14) 111 (18) 111 (17) Craniofacial 97 (17) 88 (16) 99 (17) 89 (14) 98 (18) 105 ( ETHYLENE GLYCOL DOSE RATE 183 dose (54.9 mg) relative to the low dose (0.42 mg) (Fig. 4) . Expressed as a percentage of total dose administered, urinary GA accounted for 1.3% of the total dose at 100 mg/kg but 18.3% of the 1000 mg/kg dose. GA levels in exocoelomic fluid and embryos were similar to one another but were consistently higher than their corresponding maternal blood levels (Fig. 3C ). At the lowest dose level (100 mg/kg), GA in exocoelomic fluid and embryos was approximately twofold to fourfold higher than corresponding maternal blood levels for the first few hours after dosing. After 6 h, the levels of GA in exocoelomic fluid decreased to the low levels found in maternal blood, whereas levels in embryos were maintained at detectable levels through 24 h. At 1000 mg/kg, embryo GA ranged from 1.4-to 3.1-fold higher than maternal blood for the first 12 h. By 24 h, GA levels in the embryo decreased to maternal blood levels, whereas the exocoelomic fluid levels remained slightly elevated (opposite of what occurred at 100 mg/kg).
The concentrations of oxalic acid in maternal and conceptus tissues were generally near the levels found in a small number of control samples (0-10 lg/g), were highly variable, and showed little evidence of clearance. Thus, it was unclear how much of the oxalic acid present in these samples resulted from the administered doses of EG versus reflecting endogenous metabolism or metabolism of constituents in the rodent diet. Oxalic acid in urine only accounted for 0.5-1.33% of the administered dose, similar to the results of Pottenger et al. (2001) , where oxalic acid accounted for only 0.36-0.66% of the EG dose over an oral gavage dose range of 10-2500 mg EG/kg.
Infusion (slow dose rate). As observed in the gavage group, EG levels in the kidneys, exocoelomic fluid, and embryos following continuous infusion were similar to the corresponding maternal blood levels (Fig. 3B) . Total urinary excretion of EG following oral gavage of 1000 mg/kg was similar to that of the 1000 mg/kg infusion, which, based on the relatively constant proportion of EG excreted in urine regardless of dose (Marshall, 1982) , suggested that the infusion pumps delivered the targeted total dose of EG (Fig. 4) . Also consistent with the gavage study was the finding that GA levels were 1.2-to 1.5-fold higher in maternal kidney and 1.6-to 2.8-fold higher in the embryo and exocoelomic fluid relative to maternal blood (Fig. 3D) . Oxalic acid concentrations in all fluids and tissues were near background (0-10 lg/g) and quite variable.
Impact of dose rate on pharmacokinetics. Comparison of the 1000 mg/kg infusion versus gavage groups revealed that peak EG levels in maternal blood, kidney, embryo, and exocoelomic fluid were approximately 8-to 11-fold higher following gavage relative to infusion (Table 4 , Fig. 2) . However, the impact of dose rate on GA kinetics was much more dramatic. Peak GA levels in maternal blood, kidney, embryo, and exocoelomic fluid were 59, 100, 49, and 56 times higher, respectively, in the gavage group than in the infusion groups. Total urinary GA collected over 24 h was 15-fold higher when 1000 mg/kg EG was given via gavage versus infusion. Differences in 24-h AUC values ranged from 16-to 38-fold higher for gavage versus infusion for all tissues and fluids analyzed.
DISCUSSION
Research linking the developmental toxicity, mode of action, and pharmacokinetics of EG has been underway for a number of years with an aim toward refining human health risk assessments of this high production volume chemical. This integrated research program had already established that EG developmental toxicity required administration of very high doses and that saturation of GA oxidation was an essential step in the mode of action (Corley et al., 2005b was hypothesized that developmental toxicity in rats required GA levels > 2mM in maternal blood and > 3mM in the embryo (Corley et al., 2005b) . These putative threshold values have been widely accepted (e.g., NTP-CERHR, 2004) , and it is readily appreciated that very high doses, particularly by the gavage route, are necessary to exceed these threshold values, whereas this is highly unlikely for nongavage exposures. Nonetheless, the gavage route of exposure has become entrenched in regulatory assessments for developmental toxicity, and there often is reluctance to base risk assessments and classification/labeling decisions on nongavage studies, even when these studies are available and human exposures occur by nongavage routes.
To further our understanding of the impact of gavage versus other modes of human exposure, the present study examined the variable of dose rate and its impact on pharmacokinetics and developmental toxicity. To model a high dose, but low dose-rate scenario, a novel sc implantable and refillable springloaded infusion pump system was utilized which allowed for the maintenance of maternal blood GA levels at~1mM, i.e., below the putative threshold, continuously from GD 6-15. Developmental outcomes following this slow dose-rate regimen were compared with those of rats given equivalent doses of EG in the form of daily sc bolus injections for the same period of time. Based on prior knowledge of EG kinetics, it was expected that the blood levels of the sc bolus group dams would each day temporarily exceed 2mM of the GA 4 . Mean values for G D11-12 24-h urinary excretion of EG, GA, and oxalic acid from CD rats following either GD 11 gavage (fast dose rate) or GD 11-12 constant-rate infusion (slow dose rate), after repeated exposures to EG from GD 6 through GD 11-12.
ETHYLENE GLYCOL DOSE RATE 185 metabolite, which would then rapidly clear to undetectable levels by 18-24 h postdose (Carney et al., 1999) . Pharmacokinetic analyses in the present study verified that the sc bolus injections achieved GA concentrations greater than 2mM, whereas the infusion groups maintained GA concentrations below 2mM (Fig. 2B) . In support of the hypothesis, developmental toxicity was observed in fetuses from dams given EG as a bolus, whereas no developmental effects were observed when the same doses of EG were given by infusion. The effects in the sc bolus groups were consistent with those seen in previous studies in which similar doses were given by gavage (Carney, 1994) .
These results also provided further support that a high C max , rather than AUC, is the key driver for developmental toxicity. As seen in Table 3 , AUC values for embryonic GA were nearly identical in the gavage 1000 mg/kg group (52.1mMÁh) and 2000 mg/kg infusion groups (50.5mMÁh), yet only gavage exposure resulted in developmental toxicity. In contrast, C max values for embryonic GA were quite different in the 1000 mg/kg gavage group (6.3mM) versus the 2000 mg/kg infusion group (2.4mM), and these differences were correlated with developmental toxicity. Finally, a remarkable degree of correspondence was evident between the C max value (6.3mM) for the 1000 mg/kg gavage group (the in vivo LOEL for developmental toxicity) and the LOEC (6.0mM) identified in rat whole-embryo culture (Carney et al., 1996; Klug et al., 2001) . This consistency across in vivo developmental toxicity, in vivo toxicokinetics, and in vitro whole-embryo culture data provides a significant degree of confidence in these conclusions.
The second part of this study examined the impact of dose rate on pharmacokinetics. Although numerous kinetic studies have been conducted on EG given to male, female, and pregnant rats, this was the first comprehensive study to include specific analysis of EG, GA, and oxalic acid in maternal target organs (kidney), as well as the developing embryo, and the exocoelomic fluid contained within the visceral yolk sac placenta. A time-course assessment was conducted during GD 11-12, a time period known to show high susceptibility to EGinduced teratogenic effects (Khera, 1991) . Dose rate only had a moderate effect on the kinetics of unmetabolized EG and essentially no impact on oxalate. The fact that oxalate remained relatively constant across a large dose range further supports its lack of a causative role in EG developmental toxicity. The lack of change in oxalate despite large differences in levels of the upstream metabolite, GA (Fig. 4) , is explained by differences in conversion and respiratory elimination of CO 2 as shown by others (Frantz et al., 1996a) . Based on previous rat developmental toxicity and pharmacokinetic data (Corley et al., 2005a,b; NeeperBradley et al., 1995) , oxalate-induced kidney toxicity and secondary effects on pharmacokinetics were unlikely to have been present given the doses and relatively short durations of exposure evaluated in this study.
In contrast, the effect of dose rate on the kinetics of its metabolite and proximate teratogen, GA, was dramatic. Peak GA levels in maternal and conceptus tissues/fluids were 49-100 times higher when 1000 mg/kg of EG was given by oral gavage relative to an equivalent daily dose given by infusion. AUCs also were higher in the gavage group relative to infusion, but the differences were not as great (16-to 38-fold). The profound impact on GA kinetics, especially C max values, is consistent with the saturation of GA's metabolism to glyoxylic acid ( Fig. 1) , which is the key rate-limiting step in EG's metabolic pathway. Another noteworthy finding was that the concentrations of GA in exocoelomic fluid and embryos were consistently higher (1.4-to 3-fold) than maternal blood levels (Figs. 3C and 3D) , particularly for the first 6-12 h postdose. These ratios are very similar to those reported in an initial developmental kinetics study (Carney, unpublished data) where exocoelomic fluid levels of GA ranged from 1.3-to 1.8-fold higher than corresponding maternal blood levels in the first 3 h after dosing with either 500 or 2500 mg/kg EG by oral gavage. Most likely the higher levels of GA in rat exocoelomic fluid and embryo were due to pH-dependent ion trapping, driven by the more alkaline pH of rat exocoelomic fluid relative to maternal blood (Carney et al., 2004; Nau and Scott, 1986; Scott and Nau1987; Srivastava et al., 1991) . The results of this study strongly support the hypothesis that dose rate is a critical determinant of EG developmental toxicity, a phenomenon which is related to the saturation of the metabolism of GA, the proximate teratogen. Quantifying the effect of dose rate is important to human risk assessment because the most common routes of human exposure to EG are dermal, characterized by very slow rates of absorption (Saghir et al., 2010; Sun et al., 1995) , or secondarily, inhalation, for which exposures tend to be spread out over time (NTP-CERHR, 2004) .
Although the data support a value of 2mM peak maternal blood GA as the critical internal dose metric differentiating safe from potentially teratogenic EG exposures, the preferential disposition of GA in the rat embryo indicates that the critical dose metric at the level of the embryo is even higher. As mentioned previously, rat whole-embryo culture studies identified no-observeable and LOEL concentrations of 3 and 6mM, respectively, following 48 h of continuous exposure to these test concentrations (Klug et al., 2001) . Comparative data suggest that it may be even more difficult to achieve these GA concentrations in the human embryo based on the fact that the celomic fluid of the first trimester human conceptus is~0.2 pH units more acidic than the maternal blood (Jauniaux et al., 1994) . Based on GA's pKa (3.83), the size and direction of the maternal blood-conceptus fluid pH gradient in humans and application of the Henderson-Hasselbach acid-base distribution equation, one would predict GA concentrations in the human conceptus to be approximately half those of maternal blood GA. Interestingly, the yolk sac cavity fluids surrounding the rabbit embryo also are acidic with respect to maternal blood (Tornesi and Carney, 2003) . Embryonic GA levels in the rabbit are correspondingly less than those of the maternal blood (Carney et al., 2008) , and EG is not developmentally toxic in the rabbit, even following gavage exposure to doses as high as 2000 mg/kg/day (Tyl et al., 1993) .
Finally, the findings from this study have broader implications for the practice of developmental toxicity testing, as regulatory guidelines for prenatal developmental toxicity studies in animals require testing at maximally tolerated doses, with gavage as the default route of exposure. This study exemplifies the tremendous disparities in pharmacokinetics that can occur following high-dose and high dose rate exposures relative to expected kinetic profiles at lower doses and dose rates. Increasingly, the wisdom of high-dose and high dose rate exposures, which run the risk of inducing shifts to nonlinear kinetics, is being questioned for the evaluation of chemicals present at low levels in the environment. For these types of chemicals, an alternative approach to the maximum-tolerated dose garnering support calls for setting the high-dose level based on the point of transition to nonlinear kinetics, supported by information on internal dose, so as to increase relevance of the data to humans (Saghir et al., 2009 ). In the case of EG, we can see clearly that high-dose gavage studies cause a shift from linear to nonlinear GA kinetics, which appears to be a prerequisite for EG-induced developmental toxicity. However, most human exposures involve much lower doses occurring via the dermal or inhalation routes, which are nonbolus. Given our understanding of GA kinetics, it is clear that gavage studies greatly overestimate the risk of typical environmental and workplace exposures, which occur by the dermal and inhalation routes and are characterized by low doses and/or low dose rates.
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